• Completed

NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE

Updated: Jun 13

THE ASPIRE TRIAL


Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

KRd Vs Rd

ASPIRE TRIAL

The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.


Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma


Sponsor

Amgen


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT01080391


Official Title: A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

First Posted : March 4, 2010


Click here for details on ClinicalTrials.gov

 

Carfilzomib Lenalidomide Dexamethasone

 

Publications:


Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

N Engl J Med. 2015 Jan 8

https://pubmed.ncbi.nlm.nih.gov/25482145/


Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

Hematol Oncol. 2018 Apr

https://pubmed.ncbi.nlm.nih.gov/29446103/


Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol. 2016 Nov 10

https://pubmed.ncbi.nlm.nih.gov/27601539/


Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment -

This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide

Blood Cancer J;2017 Apr 21

https://pubmed.ncbi.nlm.nih.gov/28430175/

 

- Arizona: Mayo Clinic Arizona

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Illinois: Rush University Medical Center Chicago

- Minnesota: Mayo Clinic Rochester Minnesota

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New York: NYU Langone Medical Center New York

- Texas: The University of Texas MD Anderson Cancer Center Houston

- Texas: UT Southwestern Medical Center Dallas

- Texas: Baylor University Medical Center Dallas

- Wisconsin: Froedtert Memorial Milwaukee

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Florida

United States, Illinois

United States, Indiana

United States, Kansas

United States, Michigan

United States, Minnesota

United States, New Jersey

United States, New York

United States, Tennessee

United States, Texas

United States, Washington

United States, Wisconsin

Canada, Alberta

Canada, British Columbia

Canada, Manitoba

Canada, Newfoundland and Labrador

Canada, Ontario

Canada, Quebec

Europe

United Kingdom

Austria

Belgium

Bulgaria

Czechia

France

Germany

Greece

Hungary

Italy

Netherlands

Poland

Romania

Serbia

Spain

Sweden

Asia

Russian Federation

Israel

Posts Archive